At the European Society for Medical Oncology (ESMO) Virtual Congress 2020 this week, detailed presentations will be 

biosimilar studies for agents from Mylan, Samsung Bioepis, and Shanghai Henlius Biotech.

Investigators plan to report phase 3 efficacy and safety data for Mylan’s proposed bevacizumab biosimilar MYL-14020 versus the reference product, Avastin, in the first-line treatment of patients with stage IV nonsquamous non–small cell lung cancer.

Investigators randomized 671 patients to the biosimilar candidate (n = 337) and Avastin (n = 334). In the preconference abstract, they reported that the confidence intervals for objective response rate (ORR) were within the predefined equivalence margins, demonstrating equivalence for MYL-14020.

 that the FDA had accepted its 351(k) filing application for MYL-14020. An application decision date was scheduled for December 27, 2020.

A poster on a randomized equivalence study for the Shanghai Henlius Biotech trastuzumab biosimilar (HLX02) also will be presented at ESMO. The multicenter study randomized women (N = 649) 1:1 to receive intravenous HLX02 or a European Union–marketed version of reference trastuzumab combined with docetaxel, with the primary end point being ORR at week 24.

In their preconference abstract, the investigators reported a 71.3% ORR for HLX02 vs 71.4% for the reference product. The group difference of 

7.0% to 6.9%) was “completely within the predefined equivalence margins of ±13.5%.”

In June, Henlius and Accord received a positive 

 for marketing approval for HLX02 from the European Medicines Agency.

Samsung Bioepis reported phase 3 exploratory 

 for its bevacizumab biosimilar (Aybintio) ahead of the scheduled ESMO poster presentation.

Articles

ESMO Virtual Congress 2020

Positive results emerging on oncology biosimilars will be presented at the European Society for Medical Oncology Virtual Congress 2020 this week . 

Positive Equivalency Data for a Trio of Biosimilars Are Reported

positive phase 3 exploratory study results for its bevacizumab biosimilar, Aybintio, which received European Commission 

The findings are set for presentation at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, which begins this week.

The Incheon, Republic of Korea–based company said the study results supported preexisting evidence in support of equivalence between Aybintio and reference bevacizumab in patients with metastatic or recurrent nonsquamous non–small cell lung cancer.

“The data observed in the phase 3 exploratory analyses reinforce equivalent clinical efficacy between Aybintio and reference bevacizumab,” said Seongwon Han, vice president and leader of the Medical & Lifecycle Safety Team at Samsung Bioepis.

The exploratory study enrolled 665 patients, of whom 337 received Aybintio and 328 were treated with reference bevacizumab with paclitaxel and carboplatin every 3 weeks for up to 6 cycles, followed by Aybintio or reference bevacizumab maintenance monotherapy. The risk difference was analyzed in the per-protocol set (PPS) within a predefined equivalence margin of ±12.5%.

The primary end point was overall response rate (ORR) after 24 weeks of induction therapy. In a previous analysis, the ORR in the PPS was 50.1% for Aybintio and 44.8% for reference bevacizumab, and the risk difference by week 24 was 5.3% (95% CI, 

2.2% to 12.9%). The risk difference is a comparative measure of the likely harms and benefits of therapies.

In the current study, the risk differences in best ORR by weeks 11 and 17 was 2.2% (95% CI, 

The mean reduction in tumor burden by week 24 was 

27.3% for reference bevacizumab, with a difference of 0.59% (

Samsung Bioepis said the results of the phase 3 exploratory analyses would be presented in an e-poster at ESMO during the virtual event’s Science Weekend on Thursday, September 17 at 9 AM Central European Summer Time.

Samsung Bioepis' bevacizumab biosimilar demonstrates equivalence in analyses to be presented at the European Society for Medical Oncology Virtual Congress 2020.

Samsung Bioepis Reports Positive Phase 3 Results for Aybintio

Biosimilar trastuzumab (Herzuma) in combination with pembrolizumab and chemotherapy was highly effective in reducing tumor size in patients with HER2-positive advanced gastric cancer, according to results of a phase 1b/2 clinical trial.

 trial was designed to evaluate the potential of the combination therapy in light of a growing body of evidence on the positive effects of monoclonal antibodies such as trastuzumab in treating solid tumors.The findings have implications for reducing the costs of care, the authors said.

“With the costs of oncology treatments being so burdensome, the availability of biosimilar trastuzumab could reduce the overall cost by combination treatment with innovative new drugs and chemotherapy,” said Sun Young Rha, MD, PhD, chief of medical oncology at Yonsei University College of Medicine and the lead investigator of the trial, during her presentation on the results at this year's virtual 2020 American Society of Clinical Oncology Annual Meeting.

Investigators in the Republic of Korea enrolled 43 patients and treated them with pembrolizumab (200 mg, day 1), biosimilar trastuzumab (6 mg/kg, day 1), capecitabine (1000 mg/m

 twice daily, days 1-14), and cisplatin (80 mg/m

The treatment duration ranged from 1.4 to 24 months, with a median follow up of 16.1 months. The trial enrolled 43 patients and 11 remained on the regimen.

Investigators found significant tumor shrinkage in 95.3% of patients, and the overall response rate was 76.7%. They said 16.3% of patients experienced a complete response and 60.5%, a partial response. Additionally, the median progression-free survival was 8.6 months (95% CI, 7.2-16.4), and the median overall survival (OS) was 19.3 months (95% CI, 16.5-NA). The investigators also found that positive status for the PD-L1 protein for patients at diagnosis did not significantly affect OS rates.

Treatment-related adverse events (AEs) ≥ grade 3 occurred in 32 (74.4%) patients, including 17 (39.5%) cases of grade 3 or grade 4 neutropenia. Immune-related AEs occurred in 4 (10%) patients. The most common hematologic AEs were decreased neutrophil count and anemia, which occurred in 46.5% and 32.6% of patients, respectively.

Herzuma, developed by Teva Pharmaceuticals USA and Celltrion Healthcare, is indicated for treatment in patients with HER2-positive metastatic breast cancer, early breast cancer, and metastatic gastric cancer.

It was approved for use in the United States in December 2018 and 

 in March 2020, making it the fourth trastuzumab biosimilar to be approved in the United States.

The drug was approved in the European Union in November of 2017 and 

 there in May 2018. Herzuma also is approved in the Republic of Korea, Japan, and Brazil.

Rha SY, Lee CK, Kim HS, et al. Targeting HER2 in combination with anti-PD-1 and chemotherapy confers a significant tumor shrinkage of gastric cancer: A multi-institutional phase Ib/II trial of first-line triplet regimen (pembrolizumab, trastuzumab, chemotherapy) for HER2-positive advanced gastric cancer (AGC). 

. 2020;38(suppl 15; abstract 3081). doi:10.1200/JCO.2020.38.15_suppl.3081

ASCO

A phase 1b/2 trial evaluating a trastuzumab biosimilar as part of a first-line triplet regimen demonstrated significant tumor shrinkage in HER2-positive advanced gastric cancer.

Biosimilar Trastuzumab Effective in Triplet Regimen for Gastric Cancer

What do UK patients think about the process and communication used to switch to adalimumab biosimilars by the National Health Service (NHS) and the local home care trusts?

 at the European Hematology Association (EHA)’s 25th Annual Congress, EHA25 Virtual, not very much.

, even before the results of the tender for adalimumab (reference product Humira) had taken place. The United Kingdom has made no secret of its hopes of significant cost savings on a switch to biosimilar adalimumab, aspiring to save £300 million (approximately US $386 million) of its £400 million (approximately US $514 million) annual spending on adalimumab as a result of using biosimilars.

In the UK setting, self-administered biologics are delivered to patients in their homes by commercial companies that are paid for by pooled funds from the pharmaceutical industry. Once a prescription is initiated by a hospital prescriber, nurses deliver the products and teach patients how to inject their therapy at home.

Nearly 2 years in, researchers sought patient feedback on the switch process with the intent of reporting findings to NHS England. In addition, they sought to give organizations representing rheumatology, dermatology, and gastroenterology patients information to develop any future resources to help improve shared decision making (SDM).

These organizations had worked with National Health Service (NHS) to produce the materials for disseminating information to prescribers and patients, and they now wanted to know how the process was implemented and if SDM was practiced.

A working group of 4 organizations created an online survey asking questions about:

How the individual was communicated with regarding their treatment being switched to a biosimilar

Was there any choice or perceived input into the decision making process

Overall satisfaction on how the individual felt their personal preferences/needs were met

The results demonstrate how challenging the switch process turned out to be.

899 useable responses, with patients identifying as 52% rheumatology, 42% gastroenterology, and 5% dermatology patients; the remaining 1% were “more complex specialties,” the researchers said.

More than half of patients were not asked for their consent before their treatment was switched to a biosimilar adalimumab, while 40% said they gave consent. A minority (7%) couldn’t remember or were unsure if consent was given.

Three-fourths were not at all satisfied or not satisfied with the ability to decline being switched. Just 12% felt that they had been given an option to refuse the switch.

SDM “needs to be put into action not just words,” concluded the authors, who represented the National Rheumatoid Arthritis Society, 1 of the 4 organizations that created the survey. The other organizations were the National Axial Spondyloarthritis Society UK; Crohns’ & Colitis UK; and the Psorarsis Association, UK.

They said they will continue to work with NHS and other stakeholders to make SDM “a reality not just rhetoric.”

EULAR

The UK results show how challenging switching to a biosimilar can be, according to patient groups.  

Looking Back, UK Patients Unhappy With Adalimumab Biosimilar Switch

Upon admission to hospital, patients who had been taking insulin degludec (iDeg) at home may receive inappropriate dosing when switched to another insulin, and this is because physicians tend to have a poor understanding of the pharmacodynamics (PD) and pharmacokinetics (PK) of iDeg, investigators concluded in a study presented at the American Diabetes Association 80th Scientific Sessions online conference.

Lead investigator Jing H Chao, MD, and Irl B. Hirsch, MD, observed widely variable practice in transitioning patients from iDeg to insulin glargine U100 (iG100) upon admission, but for various reasons, patients with type 1 diabetes were found to be at much higher risk of developing hypo- and hyperglycemia than patients with type 2 diabetes.

A key reason for the complexity of transitioning patients from iDeg to iG100 is that iDeg has a half life of 25 hours, more than twice that of iG100, meaning it remains in the body at higher concentrations for longer, up to 42 hours versus 24 for iG100, Chao explained. Hospital-based physicians may not understand this and give patients too much or too little iG100 to maintain insulin levels following home dosing. “Physicians should judiciously determine the amount of insulin to be given,” Chao said.

Part of the reason for the knowledge deficiency may be that iDeg, a Novo Nordisk product, was FDA approved just 5 years ago. An advantage of IDeg is that it enables physicians to achieve a more stable background level of insulin in the body relative to insulin glargine, which “waxes and wanes,” Chao said.

So, when switching to iG100 upon admission, it is important to take into account the different rate at which iDeg is excreted from the body. “By the 24th hour, there is still 50% of the background degludec on board. By contrast, when you have glargine, most of the glargine has already been washed out,” Chao said. “If patients were to receive a 100% glargine dose at the 24-hour mark, that would raise their basal [or background] insulin to 150% of the basal insulin that’s on board at that point.”

In the study, Chao and Hirsch noted that clinicians gave iG100 at 0% to 100% of the home-based iDeg dose anytime between 24 hours and 72 hours after the last iDeg dose, “demonstrating a general lack of understanding of the PK and PD of iDeg and a great need to standardize this transition.”

“Physicians are giving 100% of the glargine at the 24th hour, leading to over-basalization of the insulin,” she said.  Excessive insulin can lead to hypoglycemia and, consequently, altered mental status and potential cardiovascular events, including heart attack.

“Not only do physicians vary the time at which they give the first dose of glargine, they also vary the amount of the glargine they give as compared to the home dose. That part was not surprising to us,” Chao said.

“What is surprising to us is that despite such variable practice, we did not see hypoglycemia in patients with type 2 diabetes, and the reason is that compared with type 1 diabetes, patients with type 2 diabetes have a better buffer in that they continue to secrete a small amount of insulin and continue to secrete some glucagon. These are countering hormones that buffer them and help prevent them from getting hypoglycemia as much as patients with type 1 diabetes,” she said.

Mild hypoglycemia was observed in 2 patients with type 1 diabetes, or 28.6%. there were no cases of hypoglycemia in the type 2 group (n = 32).

Another factor to consider is that patients when admitted tend to be under higher levels of physiologic stress, which causes them to require increased amounts of insulin. So, the tendency on the part of physicians to provide too much iG100 is counterbalanced by the body’s need at this point for more insulin than usual, Chao said. “For these reasons we don’t see hypoglycemia in patients with type 2 diabetes.”

“We found that, to counter the amount of stress-induced hyperglycemia, when patient receives 50% to 75% of the glargine at the 24-hour mark, which leads to total of 100% to 125% background basal insulin level at that time, their blood sugar is actually better controlled,” she said.

“If you give anything up to 49%, that gives them less than their home dose, and is insufficient to cover their basal insulin requirement during a stressful hospitalization.”

Chao and Hirsch are hoping that their study prompts physicians to think more carefully about the PD and PK of iDeg and carefully assess other factors when determining follow-up dosing, such as meals taken, stress from hospitalization, renal function, and whether patients were on a sufficient home dose of insulin to begin with. Renal considerations are key with iDec, because it is not excreted via the kidneys.

The investigators also would like to see further studies conducted, leading to the development of guidelines.

“We’re hoping that prospective trials can be conducted to take a better look at the transition to determine the recommendations on how much insulin glargine to give at what point of their patients’ hospitalization that will ensure patients safety during this complicated transition,” Chao said.

For more about insulin degludec, see these stories about 

Chao JH, Hirsch IB. degludec-to-glargine transition: the first real-world study. Poster presented at: American Diabetes Association 80th Scientific Sessions; June 12-16, 2020. Poster 1025-P.

There is much inconsistency in the way physicians transition patients from insulin degludec to insulin glargine upon hospital admission, leading to higher risk especially for patients with type 1 diabetes, according to a study presented at the American Diabetes Association 80th Scientific Sessions online conference.
 

Doctors Manage Insulin Degludec-to-Glargine Transition Poorly, ADA Study Says

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

The European Hematology Association recently held its 25th Annual Congress, EHA25 Virtual, from June 11 through June 21. The meeting was conducted on a digital platform due to the coronavirus disease 2019 (COVID-19) pandemic and featured some key study findings and presentations on the up-and-coming world of hematology biosimilars.

The following is a summary of our biosimilar coverage from this event:

Investigators produced what they described as the 

 the use of biosimilar erythropoiesis-stimulating agents (ESAs) in patients with myelofibrosis (MF)-related anemia.

Investigators said ESAs are used to manage anemia in hematological malignancies, but scarce evidence exists for the use of these agents in the treatment of MF, and available results are divergent: Response rates range from 23% to 69%, according to the abstract presented at EHA25 Virtual. Until this study, there were no data on the use of biosimilar ESAs in this setting, investigators said.

Investigators reported an 88% overall response rate for a Sandoz rituximab biosimilar in combination with chemotherapy in patients with CD20-positive diffuse large B-cell lymphoma. At the end of treatment, the complete response was 57% and partial response was 31%. Investigators said 61% and 29% of patients experienced enlarged lymph nodes and disease-related pain, respectively.

 presented this month at EHA25 Virtual confirmed findings from the REFLECT study released in 2019, which was the first prospective postapproval study to evaluate a rituximab biosimilar in this context.

 that a rituximab biosimilar developed by Celltrion Healthcare (Truxima) in combination with lenalidomide and acalabrutinib (R2A) in patients with relapsed or refractory aggressive B-cell lymphoma was tolerable and effective.

The addition of rituximab, a targeted therapy, to chemotherapy agents can improve patient outcomes but adds to the financial burden of treatment. Investigators said that exploring the use of biosimilar rituximab may be an avenue to bring down costs.

To read all of these articles, visit our EHA 

Videos

Here is a summary of our coverage from EHA25 Virtual, the annual meeting for the European Hematology Association (EHA).

EHA25 Virtual Roundup

Although adalimumab and etanercept biosimilars have been approved in the United States, these have not yet been brought to market, owing to exclusivity 

. However, European studies investigating real-world applications of these agents are well along, based on presentations at the EULAR 2020 Congress, the virtual meeting of the European League Against Rheumatism.

An Italian study at Padova University Hospital evaluated the rate of switching from originator versions of these drugs to biosimilars in patients with rheumatoid arthritis (RA), psoriatic arthritis (PSA), and axial spondyloarthritis (axSpA). Investigators also evaluated survival for patients who switched to biosimilars versus those who didn’t.

The study enrolled 1208 patients, of whom 560 (46.3%) switched to biosimilars: etanercept (n = 391) or biosimilar adalimumab (n = 169). The mean disease duration was 16 years, and the mean duration of the biologic disease-modifying antirheumatic drug (bDMARD) was 96.3 months.

Investigators said factors associated with switching were longer disease duration, shorter duration of previous bDMARD treatments, and diagnosis. Patients with RA had an almost 3-fold higher likelihood of being switched to biosmilars compared with patients with PSA or axSPA, according to the study. Investigators said the difference between PSA and axSPA in this context was not significant.

A longer drug survival was observed in patients who switched versus those who continued with originator drugs (HR 1.38; 95% CI, 1.2-1.58); however, investigators concluded that switching from the reference biologic to the biosimilar “does not affect the survival of the treatment. Indeed, it provides sustained effectiveness particularly if undertaken in patients with stable disease activity.”

They said longer drug survival was associated with longer disease duration, longer mean duration of previous bDMARDs, and diagnosis.

Investigators also concluded that “patients with longer disease duration and longer bDMARD duration were most likely to be switched successfully to biosimilars.”

In a second switching study, also conducted in Italy, investigators sought to evaluate the safety and retention rate for patients switched from the originator etanercept to the biosimilar (SB4, Benepali).

The study enrolled 220 patients with RA, PSA, and ankylosing spondylitis (AS), juvenile idiopathic arthritis (JIA), and other rheumatic diseases treated with originator etanercept for at least 6 months. Investigators collected data on adverse events, loss of efficacy, and persistence on treatment. The rate of retention, reason for discontinuation, and other management data were collected at 6, 12, and 18 months.

Investigators said the originator biologic was used in various dMARD treatment lines: first, 76.8%; second, 17.7%; third, 3.2 %; and fourth, 2.3%. At a median follow-up of 12.1 months, 50 patients (22.7%) presented with at least 1 nonserious adverse event, with 36 (16.4%) instances of disease re-activation, and 30 (13.6%) interruptions of SB4 treatment, mostly related to safety and efficacy.

They said the retention rates were 99.1% (210/212) at 6 months, 90.9% (150/165) at 12 months, and 81.5% (53/65) at 18 months, respectively.

Of the 30 interruptions in biosimilar treatment, 17 patients were switched back to the originator product; the remaining patients were given a different drug regimen. Investigators said age was the only significant predictor of interruption at 6 months.

Retention rates at 6, 12, and 18 months were not influenced by disease, bDMARD line, conventional synthetic DMARD combination, gender, disease duration or originator etanercept duration.

“Our real-life data confirm the safety profile of switching from ETN to SB4. In our patients, the data show a higher retention rate, when compared to other-real life registries data,” investigators wrote.

Astorri D, Ometto F, Friso L, Raffeiner B, Botsios C, Doria A. Use of TNF-inhibitors biosimilars in chronic inflammatory arthritides: a three-year experience in a large monocentric cohort of patients from the North-East Italy. Presented at: EULAR 2020 Congress; June 3-August 31, 2020. Abstract AB0274.

Bruni C, Gentileschi S, Capassoni M, et al. Safety and retention rate after switching from etanercept originator (ETN) to etanercept biosimilar (SB4) in inflammatory joint diseases: data from real life. Presented at EULAR 2020 Congress; June 3-August 31, 2020. Abstract AB0281.

Studies on switching and retention for adalimumab and etanercept biosimilars yielded positive data, according to abstracts presented at the EULAR 2020 Congress.
 

EULAR Studies Explore Value of Biosimilar Switching

A survey of rheumatologists in France concluded that they generally have a good understanding of biosimilars but lack the confidence to use them, according to data presented at the EULAR 2020 Congress, the virtual meeting of the European League Against Rheumatism.

The study concerned the use of subcutaneously applied tumor necrosis factor inhibitor (SC TNFi) biosimilars, which have been available in France since 2015 at lower cost than reference products. There is no requirement in France that rheumatologists prescribe biosimilars or switch patients to them.

The findings mirror the results of a similar US-based study 

 last year in which rheumatologists expressed hesitancy about switching to biosimilars and extrapolating to uses beyond those the biosimilars were approved for.

French investigators surveyed 101 rheumatologists, 47.1% of whom were younger than 40 years and 92% of whom had authorization to prescribe TNFi.

According to the findings, 53.2% always prescribe biosimilars when prescribing TNFi for the first time, and 78.5% prescribe TNFi biosimilars 90% of the time.

Investigators said 30.6% of French rheumatologists never switch patients from originator drugs to biosimilars. Those who switch patients to biosimilars do it more than 75% of the time.

In the survey, 96.5%, 87.1%, and 91.8% agreed that biosimilars are as efficient, are as safe, and have the same immunogenicity profile as originator products, respectively.

Among rheumatologists who prescribe biosimilars in more than 90% of cases, 77.4% correctly answered no to the question “biosimilars and originators have to be compared in phase III studies for each indication for which the originators received marketing approval.”

Among those who prescribe biosimilars less than 90% of the time, just 31.2% answered this question correctly, indicating to the investigators that those who prescribe biosimilars as initial treatments tend to be equipped with better knowledge of biosimilars. Investigators said this finding was significant (

Rheumatologists were also asked whether there is enough experience with biosimilars. Most rheumatologists who switch to biosimilars more than 75% of the time answered this question in the affirmative, and just 25.4% in this group said there isn’t enough experience with biosimilars.

The same question was asked of those who switch to biosimilars less than 75% of the time. Investigators said a majority of them (57.7%) answered that there isn’t enough experience with biosimilars. This finding also was significant (

De Chateaubriant A, Ingrand P, Gervais E. Anti-TNF biosimilars: how knowledge and belief influence prescription. Presented at: EULAR 2020 Congress; June 3-August 31, 2020. Abstract AB1162.

A study presented at the European League Against Rheumatism conference suggested that French rheumatologists have good knowledge of biosimilars but lack the confidence to use them.

French Rheumatologists Lack Confidence in Biosimilars, Study Says

A rituximab biosimilar (Truxima) in combination with lenalidomide and acalabrutinib (R2A) in patients with relapsed or refractory aggressive B-cell lymphoma was tolerable and effective, according to findings 

at EHA25 Virtual, the annual meeting of the European Hematology Association.

In 13 patients who underwent disease assessment following treatment with the R2A regimen, the overall response rate was 69% and the complete response rate was 31%. The 6-month progression-free survival rate was 83%. Just 1 patient experienced disease progression after an initial objective response.

The rituximab product was developed by Celltrion Healthcare and study participants were enrolled in the Republic of Korea.

“By incorporating biosimilar rituximab into combination therapies alongside new drugs, the overall cost burden can be reduced, enhancing patient access,” said Youngil Koh, PhD, associate professor at Seoul National University Hospital and lead researcher for the trial in a statement.

Diffuse large B-cell lymphoma (DLBCL) is a subtype of non-Hodgkin lymphoma that accounts for about 30% to 40% of adult cases. Although global epidemiological data are limited, DLBCL’s estimated incidence is 7 cases per 100,000 individuals. B-cell lymphoma is aggressive and often diagnosed in late stage.

About 30% to 40% of patients who have had B-cell lymphoma relapse, and 10% have refractory disease. Without treatment, patients with relapsed or refractory disease have a life expectancy of 3 to 4 months.

Investigators said 73% of patients enrolled had non-germinal center B-cell—like (non-GCB) DLBCL. Patients received rituximab 375 mg/m

 daily intravenously, lenalidomide 20 mg once daily on day 1 to day 21, and acalabrutinib 100 mg twice daily on day 1 to day 28. Each cycle of treatment was delivered over 4 weeks, and each patient received 6 cycles. Responders received acalabrutinib maintenance for up to one year.

The phase 2 study ran from July 2019 to February 2020, and median follow-up was 3.2 months for 22 patients enrolled. Dosage was reduced in 3 and 1 patients for lenalidomide and acalabrutinib, respectively, due to hematological toxicity. During a total of 61 treatment cycles, 3 patients experienced higher than grade 2 toxicity for neutropenia, thrombocytopenia, and skin toxicity, which was the most common adverse event reported and occurred in 4 (18%) patients.

“The data indicate that the R2A regimen was therefore well tolerated in Korean relapse/refractory B-cell lymphoma patients, with initial analysis in non-GCB DLBCL patients showing a promising response,” investigators wrote.

 a prequalification to Truxima, making it the first rituximab biosimilar to be certified for use by the organization.

Truxima is currently marketed in the United States under the name Rituxan and in the European Union as MabThera. It 

Truxima is a monoclonal antibody that works by binding to CD20 cells on the surface of B-cells and mediates the destruction of cancer cells.

Koh Y, Park C, Byun Jm et al. Rituximab, lenalidomide and acalabrutinib (R2A) for relapsed/refractory aggressive B-cell lymphoma: interim analysis reporting good tolerability and potential durable response. Presented at EHA25 Virtual; June 11-21, 2020. Abstract EP1272.

A rituximab biosimilar developed by Celltrion Healthcare demonstrates safety and efficacy in patients with relapsed or refractory aggressive B-cell lymphoma, in findings presented at EHA25 Virtual, the annual meeting of the European Hematology Association.
 

Celltrion Biosimilar Shows Efficacy in DLBCL Combination

In studies presented this month at the European E-Congress of Rheumatology 2020, investigators revealed 

 for the infliximab biosimilar CT-P13 (Inflectra, Remsima), which is developed by Celltrion of Incheon, Republic of Korea.

The studies concerned the influence of body mass on response for CT-P13 subcutaneous (SC) in patients with active rheumatoid arthritis (RA), the correlation between antidrug antibody (ADA) positivity and clinical outcomes in patients with RA, and the potential savings in a market scenario where patients are treated with CT-P13 SC.

The post-hoc study of body mass on clinical response to CT-P13 SC demonstrated no statistically significant differences in response between patient cohorts stratified into under/normal weight (<25kg/m

), based on World Health Organization criteria.

Investigators said the mean change from baseline in disease activity score 28-joint count C reactive protein was —3.3, –3.1, and –3.3 at week 54, respectively. The duration of low disease activity up to week 54 was 26.2, 29.2, and 27.9 weeks, and the good or moderate European League Against Rheumatism responder rates were 84.1%, 80.3%, and 90.2% at week 54, respectively.

Patients in each cohort received at least 1 full dose of CT-P13 SC following intravenous induction in the initial treatment stage prior to week 30.

“The post-hoc results showed that there was no impact of [body mass index] BMI on the clinical responses of CT-P13 SC 120 mg biweekly in RA patients. Therefore, Remsima SC could be a promising therapeutic option regardless of BMI in RA patients,” said Rene Westhovens, a rheumatologist and one of the lead investigators in the trial.

In a second study, data from a multicenter, randomized, controlled trial demonstrated that ADA positivity and titer, or solution concentration, helped to predict pharmacokinetic profile and clinical response. Investigators said CT-P13 SC administration did not lead to a higher incidence of ADA compared with CT-P13 IV and no clinical differences between the formulations were observed.

In a third study, investigators concluded that self injection of CT-P13 could significantly reduce the burden on health care delivery. Their study suggested potential cost savings of $49.7 million over 5  years in the United Kingdom from the use of CT-P13 SC. They said the money saved was equivalent to the cost of CT-P13 treatment in an additional 4466 patients.

In a second scenario, investigators estimated potential savings of $350.7 million over 5 years based on real-world dose escalation up to 5 mg/kg. This, they said, would make it possible for an additional 30,839 patients to receive treatment with the SC formulation.

“With the pressure of meeting patient need and the increasing burden on health care systems, there is a greater demand than ever to deliver new and innovative treatment options that enable patients to live more independently, reduce the time spent in hospitals and in turn, lessen the pressures put on health care systems,” said Martin Perry, a consultant rheumatologist in the Department of Rheumatology at Royal Alexandra Hospital in Paisley, United Kingdom.  

Read more about CT-P13 and a recent study that may have helped to allay concern among gastroenterologists that there is not enough evidence to support use of the agent in 

The infliximab biosimilar CT-P13 delivered positive results in studies presented at the European League Against Rheumatism's European E-Congress of Rheumatology 2020.

Latest Conference Articles